Overall LDA assignment of variant VWD phenotype
| . | LDA: number of observations and percent classified into VWD type . | ||||||
|---|---|---|---|---|---|---|---|
| Type 1 . | Type 1C . | Type 2A . | Type 2B . | Type 2M . | Type 2N . | Total by ZPMCB-VWD . | |
| ZPMCB-VWD confirmed VWD phenotype | |||||||
| VWD phenotype | |||||||
| Type 1 | 20 (19)* | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 21 |
| 95.24% (90.48%) | 4.76% (9.52%) | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) | ||
| Type 1C | 2 (2) | 27 (26) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 30 |
| 6.67% (6.67%) | 90% (86.67%) | 3.33% (6.67%) | 0% (0%) | 0% (0%) | 0% (0%) | ||
| Type 2A | 0 (0) | 3 (3) | 19 (18) | 0 (0) | 1 (2) | 0 (0) | 23 |
| 0% (0%) | 13.04% (13.04%) | 82.61% (78.26%) | 0% (0%) | 4.35% (8.70%) | 0% (0%) | ||
| Type 2B | 0 (0) | 0 (0) | 0 (0) | 23 (23) | 0 (0) | 0 (0) | 23 |
| 0% (0%) | 0% (0%) | 0% (0%) | 100% (100%) | 0% (0%) | 0% (0%) | ||
| Type 2M | 1 (2) | 0 (0) | 0 (1) | 0 (0) | 19 (17) | 0 (0) | 20 |
| 5% (10%) | 0% (0%) | 0% (5%) | 0% (0%) | 95% (85%) | 0% (0%) | ||
| Type 2N | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 16 (15) | 17 |
| 5.88% (11.76%) | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) | 94.12% (88.24%) | ||
| Total by LDA | 24 (25) | 31 (31) | 20 (21) | 23 (23) | 20 (19) | 16 (15) | 134 |
| . | LDA: number of observations and percent classified into VWD type . | ||||||
|---|---|---|---|---|---|---|---|
| Type 1 . | Type 1C . | Type 2A . | Type 2B . | Type 2M . | Type 2N . | Total by ZPMCB-VWD . | |
| ZPMCB-VWD confirmed VWD phenotype | |||||||
| VWD phenotype | |||||||
| Type 1 | 20 (19)* | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 21 |
| 95.24% (90.48%) | 4.76% (9.52%) | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) | ||
| Type 1C | 2 (2) | 27 (26) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 30 |
| 6.67% (6.67%) | 90% (86.67%) | 3.33% (6.67%) | 0% (0%) | 0% (0%) | 0% (0%) | ||
| Type 2A | 0 (0) | 3 (3) | 19 (18) | 0 (0) | 1 (2) | 0 (0) | 23 |
| 0% (0%) | 13.04% (13.04%) | 82.61% (78.26%) | 0% (0%) | 4.35% (8.70%) | 0% (0%) | ||
| Type 2B | 0 (0) | 0 (0) | 0 (0) | 23 (23) | 0 (0) | 0 (0) | 23 |
| 0% (0%) | 0% (0%) | 0% (0%) | 100% (100%) | 0% (0%) | 0% (0%) | ||
| Type 2M | 1 (2) | 0 (0) | 0 (1) | 0 (0) | 19 (17) | 0 (0) | 20 |
| 5% (10%) | 0% (0%) | 0% (5%) | 0% (0%) | 95% (85%) | 0% (0%) | ||
| Type 2N | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 16 (15) | 17 |
| 5.88% (11.76%) | 0% (0%) | 0% (0%) | 0% (0%) | 0% (0%) | 94.12% (88.24%) | ||
| Total by LDA | 24 (25) | 31 (31) | 20 (21) | 23 (23) | 20 (19) | 16 (15) | 134 |
Columns depict LDA classification from diagnostic algorithm, and rows depict ZPMCB-VWD confirmed variant VWD diagnosis. The numerical value on the top of each row is the number of subjects LDA classified into each VWD variant phenotype, and the percent in the bottom of each row is the percent of ZPMCB-VWD confirmed diagnoses that LDA classified into each VWD variant. Rows equal 100%. Numerical values in parentheses depict jackknife-resampling analysis to predict assay performance in a general population.
Jackknife analysis.